Monoclonal antibodies can be advantageous due their high specificity for molecular targets and potential to induce additional anti-tumour effects such as antibody-dependent cell-mediated toxicity (ADCC) [109], and a number of FGFR2-targeting antibodies (e.g., GP369, GAL-FR21, PRO-007 and bemarituzumab) have shown efficacy in pre-clinical models of FGFR2-amplified GC. The gene discussed is FGFR2; the disease is neoplasm.